Jordan Plans Price Increase For Imported Drugs

21 July 1996

Jordan plans to raise the prices of some imported medicines by 3.9%, according to a report in The Jordan Times. This move comes in response to claims by local drugmakers that the inflexible pricing system has hindered the development of the national drug industry, which is Jordan's main hard-currency earner (Marketletter July 15).

Abdul Rahim Issa, president of the Jordan Pharmacists Association, has confirmed that the government plans to increase the prices of some drugs registered since 1988, but he stressed the rise would not exceed 4%.

The crisis arises in part from old pricing policies which make the Jordanian dinar equivalent to $3, the pre-1989 price, rather than the current rate of $1.40. Drug firms say little profit can be made because drug prices are based on imports, and are unchanged once set. Drugs are Jordan's second-largest export, standing at $168 million in 1995, after potash.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight